首頁 › 子宮內膜癌 › 阿拉巴馬州 › Birmingham
Birmingham, AL 的 子宮內膜癌 臨床試驗
16 項針對 子宮內膜癌 的研究正在 Birmingham（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
招募中3 期
- University of Alabama at Birmingham Cancer Center, Birmingham
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
招募中2 期
- University of Alabama at Birmingham Cancer Center, Birmingham
A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)
招募中3 期
- GSK Investigational Site, Birmingham
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
招募中2 期
- UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital, Birmingham
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
招募中2 期
- University of Alabama at Birmingham Cancer Center, Birmingham
DESTINY-PANTUMOUR04
招募中觀察性研究
- Research Site, Birmingham
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
招募中1/2 期
- University of Alabama_6th Ave, Birmingham
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
招募中觀察性研究
- University of Alabama at Birmingham, Birmingham
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
招募中1 期
- University of Alabama Birmingham, Birmingham
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
招募中1/2 期
- Children's Hospital of Alabama, Birmingham
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
招募中1/2 期
- University of Alabama at Birmingham, Birmingham
The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons
招募中觀察性研究歡迎健康志工
- University of Alabama at Birmingham, Birmingham
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
招募中1 期
- University of Alabama at Birmingham, Birmingham
- University of Alabama at Birmingham, IDS Pharmacy, Birmingham
- University of Alabama at Birmingham, Birmingham
- 還有 1 項
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
招募中2 期
- 004, Birmingham
Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
招募中1/2 期
- O'Neal Comprehensive Cancer Center at UAB, Birmingham
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中觀察性研究
- Massive Bio SYNERGY-AI site, Birmingham
其他城市的 子宮內膜癌 試驗
- Houston, TX68 項研究
- New York City, NY52 項研究
- Boston, MA50 項研究
- Arlington, VA39 項研究
- Nashville, TN38 項研究
- Los Angeles, CA34 項研究
- St. Louis, MO29 項研究
- Philadelphia, PA28 項研究
- San Antonio, TX27 項研究
- Columbus, OH25 項研究
- Oklahoma City, OK25 項研究
- Chicago, IL25 項研究
Birmingham 的其他研究
- 癌症（所有類型）31 項研究
- 乳癌24 項研究
- 卵巢癌23 項研究
- 肥胖症23 項研究
- 非小細胞肺癌22 項研究
- 急性髓系白血病21 項研究
- 多發性骨髓瘤18 項研究
- 慢性阻塞性肺病17 項研究
- 心血管疾病17 項研究
- 第二型糖尿病16 項研究
- 過重16 項研究
- 囊腫性纖維化16 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。